The federal contract IDV award is for the provision of COVID-19 pediatric vaccines by Novavax Inc. (Novavax) to the Centers for Disease Control and Prevention (CDC). The $116 million IDV contract has an ultimate completion date of May 31, 2025 and is a multiple award IDV, meaning task orders will be competed among multiple awardees. Novavax has previously received federal contracts from the Department of the Army and has also served as a subcontractor on other government contracts. The purpose of this IDV is to deliver COVID-19 vaccines to support the CDC's pediatric vaccination efforts as part of the federal government's response to the pandemic. The IDV was awarded on June 1, 2024 and does not have any set-aside requirements.
Generated 1/17/25, 9:04 AM